Medical Condition News

RSS

Antioxidants can contribute to early onset of Type 2 diabetes

An international team of scientists, led by Monash University researchers, has found that anti-oxidants commonly touted for their health-promoting benefits, could contribute to the early onset of Type 2 diabetes.

8 Oct 2009

Entest BioMedical applies for Phase II grant from National Cancer Institute

Entest BioMedical, Inc. a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. announced today that it has applied for an Exploratory/Development Phase II grant from the National Cancer Institute (NCI).

8 Oct 2009

World Sight Day to focus global attention on blindness and vision impairment

World Sight Day, celebrated on October 8th, is an annual day of awareness to focus global attention on blindness and vision impairment as a major public health issue. World Sight Day is coordinated by the International Agency for the Prevention of Blindness (IAPB) under the global initiative of VISION 2020. This year, the theme for World Sight Day is Gender and Eye Health.

8 Oct 2009

Aflac raises $1.16 million through a grant campaign for pediatric cancer treatment

Aflac announced that it has raised more than $1.16 million for the Aflac Cancer Center through a matching grant campaign with Causes on Facebook, making it the largest sponsored campaign in the history of Causes. The effort also resulted in 851,215 new members joining the Aflac Cancer Center Cause, helping to generate awareness and financial support during Childhood Cancer Awareness Month.

8 Oct 2009

NIH grants over $3.8 million to Asuragen

Asuragen, Inc. announced today that it has received over $3.8 million in new grant funding for 2009 from the Small Business Innovative Research (SBIR), Small Business Technology Transfer (STTR), and American Recovery and Reinvestment Act (ARRA) funded initiatives of the National Institutes of Health (NIH) to further its development of molecular diagnostics for oncology and genetic disease.

8 Oct 2009

MENA's diabetes action plan to improve the prevention, treatment and care of diabetes

International Diabetes Federation Middle East and North Africa Region (MENA) today launched a diabetes action plan, marking a major step forward towards optimal disease management in type 2 diabetes. The MENA action plan aims to improve the prevention, treatment and care of diabetes, which has reached epidemic proportions in the region and has overtaken wider communicable diseases as a health risk.

8 Oct 2009

NCI awards $11.5 million grant to UAB for cervical cancer research

The University of Alabama at Birmingham (UAB) Comprehensive Cancer Center has won an $11.5 million grant from the National Cancer Institute (NCI) to explore groundbreaking cervical cancer research, prevention and treatment.

8 Oct 2009

Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia

Relypsa, Inc., today announced the initiation of patient enrollment in the PEARL-HF study, a Phase 2b clinical trial of the company’s lead compound, RLY5016. A novel potassium binder designed for chronic use, RLY5016 is being evaluated in the prevention and treatment of hyperkalemia, for which there are no current satisfactory treatments.

7 Oct 2009

NCI awards BioMarker Strategies a SBIR contract to develop its SnapPath live-tumor-cell testing system

BioMarker Strategies, LLC announced today that it has been awarded a Fast-Track Small Business Innovation Research (SBIR) contract from the National Cancer Institute to develop the SnapPath™ live-tumor-cell testing system. BioMarker Strategies is developing the SnapPath™ system to enable oncologists to determine the most effective drug treatment for their cancer patients.

7 Oct 2009

Zelos Therapeutics commences patient dosing of ZT-034 for treating osteoporosis

Zelos Therapeutics, Inc. has initiated patient dosing in a single dose study of three proprietary subcutaneous formulations of ZT-034 (hPTH (1-34), teriparatide). ZT-034 is being developed to compete with Eli Lilly and Company’s Forteo (teriparatide [rDNA origin]) in its existing market of approximately $800M in annual sales in 2008 for the treatment of osteoporosis.

7 Oct 2009

New lung cancer pathways discovered using computer modeling

Using computer modeling, the Translational Genomics Research Institute and Scottsdale Healthcare have discovered lung cancer 'pathways' that could become targets for new drugs, according to a scientific paper published online today by the Journal of Thoracic Oncology.

7 Oct 2009

Help Group Summit 2009 on autism, learning disabilities and ADHD

The Help Group Summit 2009 - Advances and Best Practices in Autism, Learning Disabilities and ADHD took place on Friday, October 2nd and Saturday, October 3rd at The Skirball Cultural Center in Los Angeles. This cutting edge conference featured more than 20 leading experts from across the country.

7 Oct 2009

Arizona Heart Institute partners with Arizona Research Center for the advancement of cardiovascular therapies

Arizona Heart Institute, a world leading medical facility specializing in diagnosis, treatment and prevention of heart and vascular disease, and Arizona Research Center, a dedicated provider of clinical research studies, announce a partnership in the advancement of cardiovascular therapies.

7 Oct 2009

New report on the relationship between secondhand smoke and heart disease

The dangers of secondhand smoke have led some organizations and communities to establish smoking bans in offices, restaurants, and other public venues. The effectiveness of such bans in protecting people from health risks associated with breathing environmental tobacco smoke has been a matter of continuing debate.

7 Oct 2009

Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection

Idera Pharmaceuticals, Inc. today announced that patient treatment has been initiated in a phase 1 clinical trial evaluating IMO-2125 in combination with ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection. IMO-2125 is a novel agonist of Toll-like Receptor (TLR) 9.

7 Oct 2009

Shire publishes efficacy study results of FOSRENOL and Renagel

Shire plc, the global specialty biopharmaceutical company, today announces the publication in Clinical Nephrology of findings from a head-to-head clinical study comparing the efficacy of two non-calcium based phosphate binders, FOSRENOL(R) (lanthanum carbonate) and sevelamer hydrochloride (Genzyme's Renagel(R)) in chronic kidney disease (CKD) patients on haemodialysis.

7 Oct 2009

Electrostimulation techniques for osteoarthritis still unclear

Despite twenty years of research on the use of electrostimulation techniques (TENS) for treatment of osteoarthritis in the knee, researchers still cannot say whether it reduces pain or physical disability. This is the conclusion of a Cochrane Systematic Review of electrostimulation trials in osteoarthritis

7 Oct 2009

Panel Intelligence expands patient focused market research service

Panel Intelligence, LLC, is pleased to announce expanded capabilities for patient focused market research. For 10 years, Panel Intelligence has provided actionable market intelligence in the form of primary research from clinicians and other healthcare professionals.

7 Oct 2009

HDSA honors outstanding contributors against Huntington's Disease

The Huntington's Disease Society of America (HDSA), will recognize the outstanding contributions to improving the quality of life of people with Huntington's Disease (HD) by several individuals and two organizations at the 13th annual Guthrie Awards Dinner this Thursday.

7 Oct 2009

Brain injuries in Ontario's construction industry are highest in August and October

August may be the cruellest month for brain injuries in Ontario's construction industry, but a new study shows October is not far behind.

7 Oct 2009

Medical Condition News

Antioxidants can contribute to early onset of Type 2 diabetes

Entest BioMedical applies for Phase II grant from National Cancer Institute

World Sight Day to focus global attention on blindness and vision impairment

Aflac raises $1.16 million through a grant campaign for pediatric cancer treatment

NIH grants over $3.8 million to Asuragen

MENA's diabetes action plan to improve the prevention, treatment and care of diabetes

NCI awards $11.5 million grant to UAB for cervical cancer research

Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia

NCI awards BioMarker Strategies a SBIR contract to develop its SnapPath live-tumor-cell testing system

Zelos Therapeutics commences patient dosing of ZT-034 for treating osteoporosis

New lung cancer pathways discovered using computer modeling

Help Group Summit 2009 on autism, learning disabilities and ADHD

Arizona Heart Institute partners with Arizona Research Center for the advancement of cardiovascular therapies

New report on the relationship between secondhand smoke and heart disease

Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection

Shire publishes efficacy study results of FOSRENOL and Renagel

Electrostimulation techniques for osteoarthritis still unclear

Panel Intelligence expands patient focused market research service

HDSA honors outstanding contributors against Huntington's Disease

Brain injuries in Ontario's construction industry are highest in August and October

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News